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vGlossary
Duration of pregnancy (gestation): Size of the uterus, estimated in weeks, based on clinical examination, 
that corresponds to a pregnant uterus of the same gestational age dated by last menstrual period (LMP).
Medical methods of abortion (medical abortion): Use of pharmacological drugs to terminate 
pregnancy. Sometimes the terms “non-surgical abortion” or “medication abortion” are also used. 
Routes of misoprostol administration: 
oral pills are swallowed; 
buccal pills are placed between the cheek and gums and swallowed after 30 minutes; 
sublingual pills are placed under the tongue and swallowed after 30 minutes; 
vaginal pills are placed in the vaginal fornices (deepest portions of the vagina) and the individual 
is instructed to lie down for 30 minutes.
Surgical methods of abortion (surgical abortion): use of transcervical procedures for terminating 
pregnancy, including vacuum aspiration and dilatation and evacuation (D&E). See Chapter 2, section 2.2.4 in 
the WHO Safe abortion guideline (2012)1  for a more detailed description of methods of surgical abortion. 
Human rights terminology
International human rights treaty/covenant/convention: adopted by the international community of 
States, normally at the United Nations General Assembly. Each treaty sets out a range of human rights, and 
corresponding obligations which are legally binding on States that have ratified the treaty. Annex 7 in the 
2012 Safe abortion guideline includes a list of these treaties.
Regional human rights treaties: States adopted human rights treaties in Africa, the Americas, Europe 
and the Middle East. Regional human rights bodies, such as the African Union, the Organization of 
American States, the Council of Europe, the European Union, and the League of Arab States monitor 
States’ compliance with the treaties. To date, there are no regional human rights treaties in South-East 
Asia or the Western Pacific. Annex 7 in the 2012 Safe abortion guideline includes a list of regional 
human rights treaties. 
 Human rights standards: the meaning and scope of human rights as interpreted and applied by the 
human rights bodies tasked with this work, e.g. international, regional and national courts, and human 
rights committees. 
1 Safe abortion: technical and policy guidance for health systems, second edition. Geneva: World Health Organization; 2012 (http://apps.who.int/iris/bitstream/
handle/10665/70914/9789241548434_eng.pdf).
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Executive  
summary
vii
Medical abortion care encompasses the management of various 
clinical conditions including spontaneous and induced abortion 
(both viable and non-viable pregnancies), incomplete abortion and 
intrauterine fetal demise, as well as post-abortion contraception. 
Medical management of abortion generally involves either a 
combination regimen of mifepristone and misoprostol or a 
misoprostol-only regimen. Medical abortion care plays a crucial role 
in providing access to safe, effective and acceptable abortion care. 
In both high- and low-resource settings, the use of medical methods 
of abortion have contributed to task shifting and sharing and more 
efficient use of resources. Moreover, many interventions in medical 
abortion care, particularly those in early pregnancy, can now be 
provided at the primary-care level and on an outpatient basis, which 
further increases access to care. Medical abortion care reduces the 
need for skilled surgical abortion providers and offers a non-invasive 
and highly acceptable option to pregnant individuals.
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Rationale for 
this guideline
Recommendations for the use of mifepristone and misoprostol 
for inducing abortion and for managing incomplete abortion are 
contained within the 2012 WHO guideline Safe abortion: technical and 
policy guidance for health systems. Evidence related to home use of 
medication and self-assessment is included in the 2015 WHO guideline 
Health worker roles in providing safe abortion and post-abortion 
contraception. However, a number of new studies have been published 
in more recent years providing evidence related to the timing, dosage, 
dosing intervals and routes of administration of medications to manage 
abortion, and also the timing of contraception initiation following a 
medical abortion. Hence it was critical for WHO to review the evidence 
and update its own recommendations. 
Guideline 
development process
The guideline was developed according to the principles set out in the 
WHO handbook for guideline development and under the oversight of 
the WHO Guidelines Review Committee. The core team at WHO (the 
Steering Group) was complemented by an Evidence Synthesis Team 
(EST) of experts (including two guideline methodologists) and by a 
multidisciplinary group of external technical experts who constituted 
the Guideline Development Group (GDG). 
The WHO 2012 Safe abortion guidance will be updated during 2019–2020. 
The contents of this 2018 guideline represent prioritized thematic areas 
that need to be updated more urgently, based on input from a pre-scoping 
online survey, conducted in mid-2016 among a group of experts in 
the field, and from a technical consultation and scoping meeting held 
in February 2017. Based on input received, the WHO Steering Group 
drafted an initial list of thematic issues and associated questions in PICO 
(population, intervention, comparator, outcome) format. These thematic 
issues included surgical management of abortion; however, the focus of 
this clinical guideline is medical management of abortion. A systematic 
literature search was conducted followed by review of the evidence; 
eight separate systematic reviews were undertaken. Data that informed 
the recommendations in this guideline came from a total of 140 studies 
carried out in a wide variety of settings ranging from high- to low-income 
economies. Figure 1 shows the geographical spread and number of studies 
per indication for medical management of abortion that served as the 
evidence base. The certainty of the evidence on safety, effectiveness and 
user satisfaction was assessed using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) approach.2  
2 Further information is available at: http://www.gradeworkinggroup.org/
ix
Recommendations were finalized in consultation with the GDG 
and using Evidence to Decision (EtD) frameworks that considered 
benefits, harms, values, equity, feasibility and acceptability, as well 
as implications for resource use, where available. Where there was 
limited evidence, supplemental programmatic information provided by 
experts from the field was considered. The guideline was prepared by 
the WHO Steering Group with input from the GDG. In addition to the 
GDG, several external peer reviewers who were unconnected to the 
guideline development process also reviewed and critically appraised 
the draft guideline prior to its finalization. Declarations of interest 
(DOIs) were managed according to standard procedures.
  
RESOLUTION OF 
INCOMPLETE ABORTION  24 studies
Australia, Burkina Faso, China, Denmark, Egypt, 
Finland, Ghana, India, Madagascar, Mauritania, 
Mozambique, Niger, Nigeria, Republic of Maldova, 
Senegal, South Africa, Sweden, Thailand, Turkey, 
Uganda, United Kingdom, United Republic of Tanzania,  
United States of America (USA), Viet Nam
INDUCED ABORTION FOR 
FETAL DEMISE 16 studies
Australia, India, Iran, Netherlands, Pakistan, Sudan, 
Thailand, Turkey, USA, Viet Nam
INDUCED ABORTION  
< 12 WEEKS 49 studies
Armenia, Canada, China, Cuba, Georgia, Hong Kong SAR, 
Hungary, India, Iran, Kazakhstan, Mongolia, Mozambique, 
Nepal, Republic of Moldova, Romania, Scotland, Serbia, 
Slovenia, South Africa, Sweden, Thailand, Tunisia, Ukraine, 
United Kingdom, USA, Viet Nam
INDUCED ABORTION  
≥  12 WEEKS 44 studies
Australia, Armenia, Canada, China, Cuba, Finland, 
Georgia, Hungary, Hong Kong SAR, India, Nepal, New 
Zealand, Singapore, Slovenia, South Africa, Sweden, 
Thailand, Tunisia, Turkey, United Kingdom, USA, 
Uzbekistan, Viet Nam
TIMING OF POST-ABORTION 
CONTRACEPTION 7 studies
Finland, Mexico, Portugal, Sweden,  
United Kingdom, USA
FIGURE 1  Evidence base informing the recommendations
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Overview of 
recommendations:  
This guideline focuses exclusively on medical management of abortion. 
It provides new recommendations related to the following indications: 
medical management of incomplete abortion at ≥ 13 weeks of gestation3  
(Recommendation 1b), medical management of intrauterine fetal demise 
at ≥ 14 to ≤ 28 weeks of gestation (Recommendation 2), timing of 
post-abortion hormonal contraception initiation (Recommendation 4a) 
and timing of post-abortion IUD placement (Recommendation 4b). 
In addition, this guideline includes updated recommendations related 
to the following indications: medical management of incomplete 
abortion at < 13 weeks of gestation (Recommendation 1a), and medical 
management of induced abortion at < 12 weeks (Recommendation 3a) 
and at ≥ 12 weeks (Recommendation 3b). 
³ Duration of pregnancy (gestation): Size of the uterus, estimated in weeks, based on clinical examination, that 
corresponds to a pregnant uterus of the same gestational age dated by last menstrual period (LMP).
RECOMMENDATIONS
COMBINATION REGIMEN  
(RECOMMENDEDª)
MISOPROSTOL-ONLY  
(ALTERNATE)
MIFEPRISTONE   MISOPROSTOL MISOPROSTOL 
 1A. INCOMPLETE ABORTION 
<  13 WEEKS
None
Use  
misoprostol-only 
regimen
600 μg POb   
or 400 μg SLb
 1B. INCOMPLETE ABORTION 
≥  13 WEEKS
None
Use  
misoprostol-only 
regimen
400 μg  
B, PV or SL  
  every 3 hoursb
 2. INTRAUTERINE FETAL DEMISE 
≥ 14–28 WEEKS
200 mg 
PO once
400 μg  
PV or SL  
 every 4–6 hoursb
400 μg  
SL (preferred) or PV 
 every 4–6 hoursb
 3A. INDUCED ABORTION 
<  12 WEEKS
200 mg  
PO once
800 μg  
B, PV or SLb
800 μg  
  B, PV or SLb
 3B. INDUCED ABORTION   
≥  12 WEEKS
200 mg  
PO once
400 μg  
B, PV or SL  
  every 3 hoursb
400 μg  
B, PV or SL  
  every 3 hoursb
TIMING OF POST-ABORTION CONTRACEPTION
IMMEDIATE INITIATION
 4A. HORMONAL CONTRACEPTION Immediately after the first pill of the medical abortion
 4B. IUD With assessment of successful abortion
xi
B: buccal ; PO: oral ; PV: vaginal ; SL: subl ingual
a Combinat ion regimen is  recommended because i t  is  more effect ive.
b Repeat doses of  misoprostol  can be considered when needed to achieve success of  the abort ion process. In this  guidel ine we 
do not provide a maximum number of  doses of  misoprostol . Health-care providers should use caut ion and c l in ical  judgement 
to decide the maximum number of  doses of  misoprostol  in pregnant indiv iduals  with pr ior  uter ine incis ion. Uter ine rupture is  a 
rare compl icat ion; c l in ical  judgement and health system preparedness for  emergency management of  uter ine rupture must be 
considered with advanced gestat ional  age.
1–2 DAYS
TABLE 1 Summary chart of recommendations on 
medical management of abortion
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Notable differences 
between this guideline 
and previous guidance 
There are several notable differences between this guideline and 
previous (2012) WHO guidance, including the time period between 
mifepristone and misoprostol dosing, the use of a loading dose, and 
the maximum number of doses of misoprostol.
4 Safe abortion: technical and policy guidance for health systems, second edition. Geneva: World Health 
Organization; 2012 (http://www.who.int/reproductivehealth/publications/unsafe_abortion/9789241548434/en/).
TOPIC THIS GUIDELINE (2018) SAFE ABORTION  GUIDELINE (2012)4 
TIME PERIOD BETWEEN 
MIFEPRISTONE AND 
MISOPROSTOL DOSING 
Time period is in days rather  
than hours
Time was provided in hours  
(i.e. 36–48) for induced abortion 
regimens with pregnancies 
beyond nine weeks 
LOADING DOSE 
The use of a loading dose of 
misoprostol is not necessary 
Previous guidance recommended 
a loading dose that differed from 
subsequent doses of misoprostol 
for induced abortion regimens with 
pregnancies beyond nine weeks
MAXIMUM NUMBER OF 
DOSES OF MISOPROSTOL
In this guideline we do not 
provide a maximum number  
of doses of misoprostol 
Previous guidance recommended  
a maximum number of five doses
TABLE 2
Notable differences between information  
in this guideline and previous guidance 
xiii
Estimation of duration 
of pregnancy (gestation) 
In this guideline, duration of pregnancy (gestation) is the size of 
the uterus, estimated in weeks, based on clinical examination, that 
corresponds to a pregnant uterus of the same gestational age dated 
by last menstrual period (LMP). Where it is difficult to determine 
uterine size based on clinical examination, alternate methods of 
pregnancy dating can be used (i.e. LMP or ultrasound).
LIMITATIONS TO DATING 
BY UTERINE SIZE ON 
PHYSICAL EXAMINATION
KEY CONSIDERATIONS
A UTERUS THAT IS SMALLER THAN 
EXPECTED MAY INDICATE: 
A UTERUS THAT IS LARGER THAN 
EXPECTED MAY INDICATE:
• uterine malformations/
fibroids
• multiple gestation
• marked uterine 
retroversion
• obesity
• molar pregnancy
• the woman is not pregnant
• inaccurate menstrual dating
• ectopic pregnancy or abnormal 
intrauterine pregnancy,  
e.g. spontaneous or  
missed abortion
• inaccurate menstrual dating
• multiple gestation
• uterine abnormalities,  
such as fibroids
• molar pregnancy
UTERINE SIZE ( IN WEEKS)
AFTER 4 WEEKS OF GESTATION 
 THE UTERUS INCREASES IN SIZE BY 
APPROXIMATELY 1 CM PER WEEK
AFTER 15–16 WEEKS OF GESTATION  
THE UTERUS REACHES THE MIDPOINT BETWEEN 
THE SYMPHYSIS PUBIS AND THE UMBILICUS
AFTER 12 WEEKS OF GESTATION  
THE UTERUS RISES OUT OF THE PELVIS
AT 20 WEEKS OF GESTATION 
THE UTERUS REACHES THE UMBILICUS
AFTER 20 WEEKS OF GESTATION  
FUNDAL HEIGHT IN CENTIMETRES 
MEASURED FROM THE SYMPHYSIS 
PUBIS APPROXIMATES THE WEEKS 
OF GESTATION
Source: Clinical practice handbook for safe abortion. Geneva: World Health Organization; 2014, p. 17 (http://www.who.int/reproductivehealth/
publications/unsafe_abortion/clinical-practice-safe-abortion/en/); adapted from Goodman S, Wolfe M; TEACH Trainers Collaborative Working 
Group. Early abortion training workbook, third edition. San Francisco (CA): UCSF Bixby Center for Reproductive Health Research and Policy; 
2007 (http://www.teachtraining.org/trainingworkbook/earlyabortiontrainingworkbook.pdf).
FIGURE 2
Pregnancy dating by physical examination  
(bimanual pelvic and abdominal examination)
2 4 8 12 16 20 30 40
xiv
1. Introduction
11.1 Background 
Mifepristone and misoprostol in combination or misoprostol alone 
are the medications generally used to induce abortion and to 
manage incomplete abortion or intrauterine fetal demise (IUFD). 
These medications are increasingly available globally, and they are on 
the World Health Organization (WHO) List of Essential Medicines (1). 
Mifepristone is an anti-progestin which binds to progesterone 
receptors, inhibiting the action of progesterone and hence 
interfering with the continuation of pregnancy. Treatment regimens 
entail an initial dose of mifepristone followed by administration 
of a synthetic prostaglandin analogue, misoprostol, which induces 
cervical softening and dilation and enhances uterine contractions, 
which aids in expelling the products of conception (2,3). 
Misoprostol is a prostaglandin E1 analogue that can be used either in 
combination with mifepristone or on its own (4–6). Misoprostol has 
a wide range of reproductive health applications, including induction 
of labour, management of spontaneous and induced abortion, and 
prevention and treatment of postpartum haemorrhage (7). Due to 
the ease of handling and storing it, as well as its non-invasiveness 
and proven cost-effectiveness, the use of misoprostol within abortion 
care – either in combination with mifepristone or alone – offers several 
advantages. It reduces the need for skilled surgical abortion providers, 
equipment, sterilization and anaesthesia, while offering a non-invasive 
and highly acceptable option to pregnant individuals (8). For these 
reasons, and because it is stable at room temperature within its 
packaging, misoprostol is particularly useful in low-resource settings (7). 
Medical abortion plays a crucial role in providing access to safe, 
effective and acceptable abortion care. Previous guidance published 
by WHO, including Safe abortion: technical and policy guidance for 
health systems (2012), provided recommendations for the use of 
mifepristone and misoprostol in combination or misoprostol alone for 
the management of medical abortion (6). The 2012 guidance stated 
that many interventions in medical abortion care, particularly those 
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in early pregnancy, can be provided at the primary care level and on 
an outpatient basis, which further increases access to care (6). In 
both high- and low-resource settings, the use of medical methods 
of abortion have contributed to task shifting and sharing and more 
efficient use of resources (9). Given the nature of the medical abortion 
process, it is also possible for individuals to play a role in managing 
some of the components by themselves, outside of a health-care facility. 
Another existing WHO guideline, Health worker roles in providing safe 
abortion and post-abortion contraception (2015), recommends that in 
specific circumstances, individuals may self-manage their mifepristone 
and/or misoprostol medication without direct supervision of a 
health-care provider, as well as self-assess the success of the abortion 
process using pregnancy tests and checklists (10) (see Box 1). It should 
be noted that pregnancy tests used to self-assess the success of the 
abortion process are low-sensitivity urine pregnancy tests, which are 
different from those tests commonly used to diagnose pregnancy. Such 
self-assessment and self-management approaches can be empowering 
for individuals and help to triage care, leading to a more optimal use of 
health-care resources.
All individuals who can become pregnant, including women, girls 
and those with varying gender identities, and who seek medical 
abortion care should be provided with all of the necessary information 
to make an informed decision to ensure the promotion of their 
health and human rights, including sex and gender equality and 
non-discrimination. With this information, individuals can decide freely 
and responsibly the number, spacing and timing of their children (11). 
It is the right of every person, regardless of marital status, to enjoy the 
benefits of scientific progress and its applications (11). 
Depending upon the context, unmarried individuals, adolescents, 
those living in extreme poverty, individuals from ethnic minorities, 
refugees and other displaced persons, people with disabilities, and 
those facing violence in the home may be vulnerable to inequitable 
access to safe abortion services. Adolescents, in particular, are less 
likely than adults to be able to obtain legal and safe abortions 
to terminate their pregnancies. Some of the barriers adolescents 
face include requirements for third party authorizations (including 
parental consent) and financial constraints (inability to pay the 
required fees) (6,12). Additional considerations related to the care 
of adolescents can be found in section 4 (General implementation 
considerations), and in the WHO adolescent job aid (13).
Where geographic inequities exist, people must travel greater 
distances for care, thereby raising costs and delaying access (14). 
Financing mechanisms should ensure equitable access to 
good-quality services (15). Where individuals are charged fees 
for abortion, such fees should be matched to their ability to pay, 
All individuals who 
can become pregnant, 
including women, girls 
and those with varying 
gender identities, and 
who seek medical abortion 
care should be provided 
with all of the necessary 
information to make an 
informed decision to 
ensure the promotion of 
their health and human 
rights, including sex 
and gender equality and 
non-discrimination.
3and procedures should be developed for exempting the poor and 
adolescents from paying for services. As far as possible, abortion 
services should be mandated for coverage under insurance plans. 
Abortion should never be denied or delayed because of inability to 
pay. Providers of abortion services should ensure that all individuals 
are treated with respect and without discrimination.
Health-care providers, health managers, policy-makers and other 
stakeholders need up-to-date, evidence-based recommendations to 
inform clinical policies and practices, to enable improved health-care 
outcomes and to provide information that is complete, accurate 
and easy to understand. Expansion of medical abortion and new 
studies related to the timing, interval and routes of administration of 
medical abortion medications, necessitated a review of the evidence 
and the development of new recommendations as well as updates to 
the WHO recommendations issued in 2012 (6). 
PREVIOUS WHO RECOMMENDATIONS RELATED TO MEDICAL ABORTION CARE WERE PRESENTED  
IN TWO WHO GUIDELINES, WHICH REMAIN CURRENT AND APPLICABLE:
Safe abortion: technical and policy guidance for health systems
This guideline was first issued in 2003 and the second edition was released in 2012 (updated based on 
evidence available for review in 2010). It provides recommendations for clinical care while addressing 
policy, programmatic and health systems considerations in the provision of safe abortion (6). Specific 
thematic areas related to medical abortion regimens contained within the 2012 edition have been 
updated in this 2018 guideline on the medical management of abortion; however, guidance on aspects 
of care provision (such as the service location and determination of success of medical abortion 
regimens) still apply, as presented in the 2012 guideline. These considerations have been placed in this 
2018 guideline either in the “Additional considerations” subsections for each recommendation or in the 
“General implementation considerations” section, which follows the “Recommendations” section. 
Health worker roles in providing safe abortion and post-abortion contraception 
This guideline was issued in 2015 (with evidence up until 2015). It contains recommendations on the 
roles of various health workers involved in abortion care, as well as on self-management of medical 
abortion (10). These 2015 recommendations remain applicable, since this 2018 guideline on the medical 
management of abortion focuses solely on the medication regimens.
BOX 1     Other relevant WHO guidance on safe abortion
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1.2 Goal and 
objectives
Goal: To provide evidence-based recommendations on the safety and 
effectiveness of abortion medications for the clinical management of 
abortion, as well as the satisfaction of users. 
Objectives: To review the evidence and develop (or update) 
recommendations related to the following focus areas.
1. Medical management of incomplete abortion at < 13 weeks and at  
≥ 13 weeks of gestation (updating the recommendations in the 2012 
WHO Safe abortion guideline (6) based on new evidence) 
2. Medical management of intrauterine fetal demise (IUFD) at  
≥ 14 to ≤ 28 weeks of gestation (new recommendation as no 
previous recommendations existed) 
3. Medical management of induced abortion at < 12 weeks and at  
≥ 12 weeks of gestation (updating the recommendations in the 2012 
WHO Safe abortion guideline (6) based on new evidence) 
4. Timing of initiation of contraception after medical abortion  
(new recommendation as no previous recommendations existed).
In this guideline, duration of pregnancy (gestation) is the size of 
the uterus, estimated in weeks, based on clinical examination, that 
corresponds to a pregnant uterus of the same gestational age dated 
by last menstrual period (LMP). Where it is difficult to determine 
uterine size based on clinical examination, alternate methods of 
pregnancy dating can be used (i.e. LMP or ultrasound). See also 
Figure 2 in the Executive summary.
51.3 Target audience 
and relevance 
The guideline is expected to be useful for:
 health-care providers;
 national and subnational policy-makers;
 implementers and managers of national and subnational 
reproductive health programmes; and
 nongovernmental and other organizations and professional 
bodies involved in the planning and management of medical 
abortion services.
While legal, policy and regulatory contexts vary, abortion is legal at 
least to save the life of the pregnant individual in most countries 
and more than two thirds of countries have one or more additional 
grounds for legal abortion (16). The provision of post-abortion care 
is always legal (10). These recommendations will be relevant across 
a diverse range of settings as the need to make care more accessible 
and rationalize the use of available health resources exists in both 
high- and low-resource settings.
62. Guideline 
development 
process
7This guideline was developed by the WHO Department of Reproductive 
Health and Research in accordance with procedures outlined in the 
WHO handbook for guideline development, second edition, 2014 (17) 
and under the oversight of the WHO Guidelines Review Committee. 
Individuals from other organizations who contributed to this guideline did 
so in their capacity as individual experts. Donors to the Department who 
fund work on abortion issues were not included among the members of 
the Guideline Development Group (GDG) and were not present at any of 
the GDG meetings. Commercial entities were not involved in developing 
the guideline, nor was funding from such sources used.
2.1 Contributors 
and their roles
The guideline was produced by the WHO Department of Reproductive 
Health and Research and the work of developing the guideline was 
coordinated by the WHO Steering Group, comprising WHO staff and 
consultants. The Secretariat was formed of members of the Steering 
Group from the Department of Reproductive Health and Research. The 
Secretariat developed the guideline questions, oversaw and participated 
in the evidence retrieval and synthesis, developed the Evidence to 
Decision (EtD) frameworks and drafted the recommendations, while 
also managing the day-to-day activities of developing the guideline.
The Evidence Synthesis Team (EST) consisted of several researchers, 
who conducted the systematic reviews, and guideline methodologists, 
who were responsible for evidence retrieval, synthesis and appraisal, 
including assisting the Steering Group to develop the EtD frameworks. 
The guideline methodologists were experts from the Global Health 
Unit, Norwegian Institute of Public Health, Oslo, Norway, and 
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Cochrane, Portland, United States of America (USA). They worked 
closely with the WHO Steering Group and researchers from the EST to 
appraise the evidence from the systematic reviews using Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) 
methodology.6 
The Guideline Development Group (GDG) was composed of 11 members 
(5 women, 6 men) from various regions who possessed expertise on a 
diverse range of relevant issues. GDG members were selected on the basis 
of their particular knowledge of clinical care for abortion, service delivery 
and health systems and their work in regions of the world where the need 
for medical guidance on abortion care is a high priority. The GDG members 
provided input into the development of the scope of the guideline, the 
formulation of the population-intervention-comparator-outcome (PICO) 
questions, the review of the evidence and the development of the 
recommendations. They also reviewed and approved the final guideline. 
A technical consultation and scoping meeting for this guideline was 
held in Geneva, Switzerland, in February 2017. Further consultation was 
conducted via email, and four subsequent GDG webinar meetings were 
held, in December 2017, March 2018, June 2018 and August 2018.
Eight individuals, external to the guideline development process and 
chosen to reflect the views of end-users who will be impacted by these 
recommendations, served as an External Review Group (ERG) for the 
draft guidelines.
A complete list of all contributors, their affiliations and roles is 
provided in Annex 1.
2.2 Declarations 
of interests
In accordance with the WHO handbook for guideline development (17), 
all members of the GDG, EST and ERG were required to complete the 
standard WHO Declaration of Interests (DOI) form. GDG members 
completed the form prior to each meeting they attended and were also 
instructed to let the Secretariat know of any changes to their declared 
interests over time. In addition, experts were requested to submit an 
electronic copy of their curriculum vitae and their biographies (which were 
posted online for a minimum of two weeks) along with the completed 
DOI form prior to each meeting. The WHO Steering Group evaluated the 
responses and discussed them with the Director of the WHO Department 
of Reproductive Health and Research. At the GDG meetings, the Chair 
presented a summary of the DOIs and all participants had the opportunity 
to confirm, append or amend any interests already declared.
6 Further information is available at: http://www.gradeworkinggroup.org/
9One individual being considered for the GDG declared an interest 
that was perceived to be a potential conflict of interest for the 
purpose of this guideline. This was discussed with the WHO Office 
of Compliance, Risk Management and Ethics (CRE). Based on the 
advice of the CRE, this individual was allowed to participate in the 
meetings as a technical resource person but did not participate in 
the development of the recommendations. No additional conflicts 
of financial interests or involvement with commercial entities were 
declared. The DOI forms and curriculum vitae have been electronically 
archived to ensure that confidentiality is maintained.
2.3 Scoping and 
formulation of the 
guideline questions
The issues to be addressed by this guideline were carefully scoped and 
refined. The initial list of concepts to be considered was developed on the 
basis of the results of a pre-scoping online survey conducted in mid-2016, 
which over 60 experts from all regions of the world were invited to 
participate in. This survey aimed to identify relevant research gaps and 
possible interventions (the survey form is provided in Annex 2). A total of 
40 responses were received. Further discussions were held via telephone or 
videoconference with the respondents. Based on input received, the WHO 
Steering Group drafted an initial list of thematic issues and associated 
questions in PICO format. The draft list of PICO questions was presented 
at the technical consultation and scoping meeting in February 2017. Most 
of those who contributed to the development of the guideline, as listed in 
Annex 1, also attended this meeting.
Preliminary PICO questions were identified, discussed, reviewed, 
modified and finalized during the scoping meeting. The final PICO 
questions for this guideline represent prioritized thematic areas that 
needed to be updated most urgently, based on input during the 
technical consultation and scoping meeting. The finalized priority 
PICO questions covered the following thematic areas: 
 medical management of incomplete abortion  
at ≥ 13 weeks of gestation;
 medical management of intrauterine fetal demise (IUFD)  
at ≥ 14 to ≤ 28 weeks of gestation;
 medical management of induced abortion  
at 9–12 weeks of gestation;
 medical management of induced abortion  
at ≥ 12 weeks of gestation;
 timing of initiation of contraception after a medical abortion. 
Several other thematic areas were noted as important, two of which 
were re-addressed in an effort to provide a more comprehensive set of 
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recommendations: 
 medical management of incomplete abortion at  
< 13 weeks of gestation; and 
 medical management of induced abortion at  
< 9 weeks of gestation.
The primary outcomes of interest were: 
 benefits and harms
• effectiveness (specific to the task) and
•  safety, i.e. serious adverse events and complications 
(specific to the task).
The secondary outcomes of interest were:
 side-effects (specific to the intervention) and
 satisfaction of users (specific to the intervention).
2.4 Evidence retrieval 
and synthesis
Evidence of safety, effectiveness and satisfaction related to the interventions 
of interest included relevant randomized controlled trials (RCTs) as well 
as non-randomized controlled trials, controlled before-and-after studies, 
interrupted time-series and cohort studies. The following databases were 
searched from inception to June 2017, without language filters. 
 International databases: ClinicalTrials.gov, Cochrane database, 
Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), Embase, Global Index Medicus (GIM), Population 
Information Online (POPLINE), PubMed.
 Regional databases: African Index Medicus (AIM), Chinese 
Biomedical Literature Database, Index Medicus for the South-East  
Asian Region (IMSEAR), Index Medicus for the Eastern 
Mediterranean Region (IMEMR), Latin American and Caribbean 
Health Sciences Literature (LILACS), Western Pacific Regional 
Index Medicus (WPRIM).
In addition, a search of trial registry sites and organizational websites, 
as well as information from experts in the field, were used to identify 
any major ongoing or completed but unpublished trials that could be 
relevant to the guideline and the recommendations.
2.4.1  Assessment of confidence in the evidence
The certainty (i.e. the extent to which one can be confident that an 
estimate of the effect or association is correct) of the evidence on 
the benefits and harms outcomes was assessed using the GRADE 
approach; two GRADE methodologists were responsible for different 
thematic issues. Five criteria – study limitations, consistency of effect, 
imprecision, indirectness and publication bias – were used to assess the 
certainty for each outcome. The level of certainty in the evidence was 
downgraded by one level for serious limitations and by two levels for 
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very serious limitations. Information about the certainty of evidence can 
be found in the justification section for each recommendation.
2.4.2  Moving from evidence to recommendations
Various factors that inform decisions on recommendations were 
assessed using the Evidence to Decision (EtD) framework method 
developed by the DECIDE collaboration (18). Developing an EtD 
framework requires explicit and systematic consideration of evidence 
on interventions in terms of specified domains: effects (benefits/
harms), values, equity, resources required, acceptability (as distinct 
from the secondary outcome of satisfaction) and feasibility.
Additional evidence of potential harms or unintended consequences 
is described in the “Additional considerations” subsection of each 
evidence summary. Such considerations include programmatic data 
that did not directly address the priority PICO question but provided 
pertinent information in the absence of direct evidence, and additional 
data extracted from other relevant sources including qualitative studies. 
2.5 Use of the 
frameworks for 
decision-making
Draft EtD frameworks were prepared by the WHO Steering Group and 
the EST. These were reviewed by the GDG and recommendations were 
subsequently drafted and then were finalized during the four GDG 
webinar meetings. In addition to the EtD frameworks, the GDG also 
had access to all the supporting materials.
Decision-making (formulation of recommendations) was based on the 
EtD frameworks and discussion of the synthesized evidence. The final 
adoption of each recommendation was consensus-driven, defined as 
full agreement among all GDG members, where possible. The final 
decision was based on majority opinion, provided the GDG members with 
opposing views were willing to agree to this outcome; voting to reach a 
final decision was unnecessary. An option for noting dissenting opinions 
was available, but at no time was it necessary to exercise this option.
2.6 Document 
preparation, revision 
and peer review
Responsible officers at WHO wrote the draft guideline. The GDG 
reviewed the draft and their feedback was incorporated. The guideline 
was also reviewed by the members of the ERG who were unconnected 
with the process of guideline development. They provided structured 
feedback on accuracy, presentation, implementation considerations 
and the overall usefulness of the guideline.
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3. Recommendations,  
rationale and  
evidence summary
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Recommendations in this guideline focus on four thematic areas and 
are presented here accordingly in subsections, as follows. 
 
Recommendations on medical regimens for the management of:
1. incomplete abortion
2. intrauterine fetal demise (IUFD)
3. induced abortion.
Recommendations on the timing of: 
4. initiation of contraception after medical abortion. 
 
Following each recommendation, the rationale and evidence summary 
are provided, followed by additional considerations and research gaps. 
The research gaps were identified using a survey that was circulated 
among the members of the Guideline Development Group (GDG) to 
indicate topics requiring further research.
Considerations relating to care provision, including location of services, 
provider type, assessment of success of the medical abortion regimen, 
and the role of ultrasound, are derived from the 2012 WHO publication, 
Safe abortion: technical and policy guidance for health systems (6). 
Information on these considerations has been included in this 
guideline under the “Additional considerations” subsections for each 
recommendation and in the “General implementation considerations” 
section, which follows this section on recommendations.
Recommendations in this guideline are presented using one of the 
following phrases: 
 We recommend the intervention (strong recommendation in 
favour of the intervention)
 We suggest the intervention (weak, conditional, discretionary or 
qualified recommendation in favour of the intervention)
Justifications for each recommendation are provided. The certainty of 
the underlying body of evidence (high, moderate, low or very low) is 
also specified.
14
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3.1 Guiding principles
Principles underlying the process of improving the access to and 
quality of abortion care include the right of access to relevant 
evidence-based health information, so that individuals who can 
become pregnant can have control over and decide freely and 
responsibly on matters related to their sexuality and reproduction 
(including their sexual and reproductive health) free of coercion, 
discrimination and violence (11). These principles also include the 
provision of additional services, for the holistic care of the patient. 
3.1.1  Provide information 
Information is a necessary component of any medical care and should 
always be provided to individuals considering abortion. At a minimum, 
this should include (6):
 the available options for abortion methods and pain 
management; 
 what will be done before, during and after the procedure, 
including any tests that may be performed;
 what they are likely to experience (e.g. pain and bleeding) and 
how long the procedure and the recovery are likely to take 
(vaginal bleeding for two weeks is normal after medical abortion 
– such bleeding can last up to 45 days in rare cases);
 how to recognize potential complications, and how and where 
to seek help, if required (individuals should return to the hospital 
or clinic if they experience increased intensity of cramping or 
abdominal pain, heavy vaginal bleeding and/or fever); 
 when normal activities can be resumed, including sexual 
intercourse (the return of fertility can occur within two weeks 
following abortion);
 where and how to access additional services and follow-up care 
(see section 3.1.4 on the right).
 3.1.2  Offer counselling 
Counselling is a focused, interactive process through which one 
voluntarily receives support, additional information and guidance 
from a trained person, in an environment that is conducive to 
openly sharing thoughts, feelings and perceptions. When providing 
counselling, it is essential to: 
 communicate information in simple language; 
 maintain privacy; 
 support the individual and ensure they receive adequate 
responses to their questions and needs; and
 avoid imposing personal values and beliefs (6).
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3.1.3  Additional services
Additional services may need to be provided to individuals seeking 
medical abortion (19). 
 Provide iron tablets for anaemia, if needed. 
 Provide any necessary pain medications. 
 Provide emotional support, if needed. 
 Refer the individual to other services as determined by 
an assessment of their needs; these services may include: 
counselling and testing for sexually transmitted infections (STIs, 
including HIV), abuse support services, psychological or social 
services, or other specialist health or medical services.
3.1.4  Follow-up care
Routine follow-up is not necessary following an uncomplicated surgical 
or medical abortion using mifepristone and misoprostol. However, an 
optional follow-up visit 7–14 days after their procedure may be offered 
to provide further contraceptive counselling and services, further 
emotional support, or to address any medical concerns.
A routine follow-up visit is recommended only in the case of medical 
abortion using misoprostol alone, to assess success of the abortion.
At the follow-up appointment: 
 assess the individual’s recovery and inquire about any signs  
or symptoms of ongoing pregnancy; 
 review any available medical records and referral documents; 
 ask about any symptoms experienced since the procedure; 
 perform a focused physical examination in response to any 
complaints; and 
 assess the individual’s fertility goals and need for  
contraceptive services. 
•  If no method was started prior to discharge from the 
facility, provide information and offer counselling and the 
appropriate contraceptive method, if desired by the client. 
•  If a contraceptive method was already started, assess the 
method used and note any concerns – where there are no 
concerns, resupply as needed; where there are concerns, 
help with selection of another appropriate method (19).
16
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3.2 Incomplete 
abortion
 3.2.1  Diagnosis of incomplete abortion
Incomplete abortion is defined by clinical presence of open cervical os  
and bleeding, whereby all products of conception have not been 
expelled from the uterus. Common symptoms include vaginal bleeding 
and abdominal pain. Incomplete abortion should also be suspected if, 
upon visual examination, the expulsed tissue is not consistent with the 
estimated duration of pregnancy. 
 3.2.2  Medical management of incomplete abortion: 
Recommendations 1a and 1b
Incomplete abortion may be managed expectantly, or treated 
surgically or medically. The mode of management to be used 
should be selected based on the individual’s clinical condition and 
preference for treatment.
7 In this guideline, duration of pregnancy (gestation) is the size of the uterus, estimated in weeks, based 
on clinical examination, that corresponds to a pregnant uterus of the same gestational age dated by last 
menstrual period (LMP).
RECOMMENDATIONS COMBINATION REGIMEN MISOPROSTOL-ONLY 
MIFEPRISTONE   MISOPROSTOL MISOPROSTOL 
INCOMPLETE ABORTION 
< 13 WEEKS
None
Use  
misoprostol-only 
regimen
600 μg POa   
or 400 μg SLa
a Repeat doses of  misoprostol  can be considered when needed to achieve success of  the abort ion process. In this  guidel ine we 
do not provide a maximum number of  doses of  misoprostol . Health-care providers should use caut ion and c l in ical  judgement 
to decide the maximum number of  doses of  misoprostol  in pregnant indiv iduals  with pr ior  uter ine incis ion. Uter ine rupture is  a 
rare compl icat ion; c l in ical  judgement and health system preparedness for  emergency management of  uter ine rupture must be 
considered with advanced gestat ional  age. 
1–2 DAYS
RECOMMENDATION 1A
Medical management of incomplete abortion  
at < 13 weeks of gestation7
PO: oral ; SL: subl ingual
For the treatment of incomplete abortion at < 13 weeks uterine size, we suggest the use of  
600 μg misoprostol administered orally or 400 μg misoprostol administered sublingually.a
RECOMMENDATION TYPE: NEW OR UPDATED
Recommendation 1a is an updated recommendation from the WHO 2012 Safe abortion guidance (6). 
The option of 400–800 μg vaginal misoprostol has been removed from this updated recommendation.
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3.2.3  Evidence summary and rationale for 
Recommendations 1a and 1b
A Cochrane review served as the evidence base for the medical 
management of incomplete abortion; the review assessed the 
effectiveness, safety and acceptability of various management 
options (20). There were 24 studies included in the review that 
focused on incomplete abortion at < 13 weeks of gestation. 
Of those 24 studies, 22 compared different doses and routes of 
misoprostol in misoprostol-only regimens and options of expectant, 
medical or surgical management. 
Effects (benefits and harms) Two studies focused on misoprostol dosage regimens; these studies 
found higher rates of successful abortion and fewer unplanned 
surgical interventions with 600 μg repeat oral dosing. In the studies 
that compared misoprostol routes, there was no clear evidence of one 
route being superior to another. In the studies that compared medical 
management with surgical or expectant management, the incidence 
RECOMMENDATIONS COMBINATION REGIMEN MISOPROSTOL-ONLY 
MIFEPRISTONE   MISOPROSTOL MISOPROSTOL 
INCOMPLETE ABORTION 
≥ 13 WEEKS
None
Use  
misoprostol-only 
regimen
400 μg  
B, PV or SL  
  every 3 hoursa
1–2 DAYS
RECOMMENDATION 1B
Medical management of incomplete abortion  
at ≥ 13 weeks of gestation
B: buccal ; PV: vaginal ; SL: subl ingual
For the treatment of incomplete abortion at ≥ 13 weeks uterine size, we suggest the use of repeat 
doses of 400 μg misoprostol administered sublingually, vaginally or buccally every 3 hours.a
RECOMMENDATION TYPE: NEW OR UPDATED
Recommendation 1b is a new recommendation.
a Repeat doses of  misoprostol  can be considered when needed to achieve success of  the abort ion process. In this  guidel ine we 
do not provide a maximum number of  doses of  misoprostol . Health-care providers should use caut ion and c l in ical  judgement 
to decide the maximum number of  doses of  misoprostol  in pregnant indiv iduals  with pr ior  uter ine incis ion. Uter ine rupture is  a 
rare compl icat ion; c l in ical  judgement and health system preparedness for  emergency management of  uter ine rupture must be 
considered with advanced gestat ional  age. 
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of successful abortion was found to be slightly lower with medical 
and expectant management, but all methods achieved high success 
rates. In all 22 studies that looked at the relevant regimens, there 
were few data on serious adverse events.
There were no studies that focused exclusively on incomplete abortion 
at ≥ 13 weeks. One study set in Finland evaluated the management 
of incomplete abortion in pregnancies up to 24 weeks of gestation, 
but it included only three women whose pregnancies fell within the 
gestational age between 13 and 24 weeks by menstrual dating (21). 
Of these three women, one received medical treatment and the other 
two received surgical intervention.
Values There was no evidence identified in the Cochrane review that looked 
directly at how women value medical abortion procedures. However, 
generally, women describe avoidance of surgery as a positive feature 
of medical management, while some women value the shorter 
abortion process and minimal bleeding associated with surgical 
management (22,23). Some women dislike the side-effects associated 
with medical management, including bleeding, fevers and chills (22,23).
Equity We were unable to identify research on aspects of equity relating to the 
relative effectiveness of the intervention in different subgroups; no 
assumptions were made.
 Resources We attempted to collect programmatic data from organizations 
involved in service delivery in order to inform the decision on how 
resources factor into the recommendation. However, we were only 
able to collect limited information, and the available data varied 
considerably in its reporting (e.g. definition of terms), thus these 
data were not used in the decision-making. In cases where additional 
hospital resources are required, such as blood transfusion, inpatient 
management or analgesic measures, we assume that the costs 
associated with this care will be higher.
 Acceptability Women generally find medical management of incomplete abortion with 
misoprostol alone acceptable and would recommend the procedure to 
a friend (24–27).
 Feasibility We were unable to identify research on the feasibility of implementing 
the use of misoprostol alone or in combination with mifepristone for 
the management of incomplete abortion. However, the Cochrane 
review included 22 studies conducted across 24 countries, providing 
information related to the varying country contexts in which such 
services may be provided. Of these 24 countries, seven were 
in low-income economies, seven were in lower-middle-income 
economies, four were in upper-middle-income economies and  
six were in high-income economies (20). 
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Rationale for Recommendation 1a (on incomplete abortion 
at < 13 weeks): Women treated with 600 μg oral misoprostol 
had higher rates of successful abortion and lower occurrence of 
additional surgical interventions; this is based on low-certainty 
evidence. Low-certainty evidence also suggests that the use of 
400 μg sublingual misoprostol leads to high rates of successful 
abortion. Acceptability of these regimens also appears high.
Rationale for Recommendation 1b (on incomplete abortion 
at ≥ 13 weeks): Due to the lack of direct evidence on medical 
management of incomplete abortion at ≥ 13 weeks of gestation, this 
recommendation is based on information extrapolated from data related 
to the medical management of abortion at > 12 weeks using misoprostol 
alone. Individuals presenting with incomplete abortion at ≥ 13 weeks
may present with varying amounts of residual tissue or products of 
conception. Thus, the GDG members took the view that since the 
regimen utilized for medical abortion at > 12 weeks is safe, effective and 
acceptable, then this regimen can also be applied to those being treated 
for incomplete abortion where expulsion of uterine contents has begun, 
as evidenced by bleeding, cramping or contractions.
3.2.4  Additional considerations
Ultrasound scanning is not routinely required for the provision of 
abortion (4,28,29). Ultrasound is useful to detect ongoing pregnancy; 
measuring endometrial thickness, however, is not generally useful 
for diagnosing incomplete abortion and may lead to inappropriate 
surgical interventions (30). 
The following health worker cadres can provide medical management 
of uncomplicated incomplete abortion, given task-specific training and 
functioning systems for monitoring and supportive supervision: auxiliary 
nurses, auxiliary nurse midwives, nurses, midwives, associate/advanced 
associate clinicians, and non-specialist and specialist doctors (10).
3.2.5  Research gaps
General:
 Identification of the most effective medical abortion regimen 
for incomplete abortion at ≥ 13 weeks of gestation (including 
the use of mifepristone in combination with misoprostol versus 
misoprostol alone) is still needed. Recommendations have been 
made for this regimen using indirect evidence. Results from the 
survey on research gaps (completed by GDG members) noted the 
lack of evidence for effective regimens in this clinical scenario 
and, therefore, further research on this topic should be pursued.
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3.3 Intrauterine 
fetal demise
3.3.1  Diagnosis of intrauterine fetal demise (IUFD)
Fetal demise refers to situations in which the fetus is no longer 
alive, but the uterus has not yet started to expel its contents and the 
cervical os remains closed (31). The diagnosis is made by ultrasound 
scan following the clinical findings, which can include vaginal 
bleeding, absent fetal heart sounds on electronic auscultation, a 
failure to feel fetal movements or a uterus that is significantly smaller 
than the expected size (31).
3.3.2  Medical management of IUFD at ≥ 14 to ≤ 28 
weeks of gestation: Recommendation 2
IUFD may be managed expectantly, or treated surgically or medically. 
The decision about the mode of management of IUFD should be based 
upon the individual’s clinical condition and preference for treatment.
Medical management of IUFD includes the use of mifepristone  
in combination with misoprostol (recommended) or misoprostol  
alone (alternate). 
3.3.3  Evidence summary and rationale for Recommendation 2 
A systematic review assessed the effectiveness, safety and acceptability 
of misoprostol treatment of IUFD at ≥ 14 to ≤ 28 weeks of gestation (32). 
A total of 16 RCTs were identified for inclusion in the review. Studies 
were included in the review if they included cases of IUFD at ≥ 14 to 
≤ 28 weeks and if these cases were evenly distributed between the 
study arms. Studies that included IUFD at < 14 weeks or > 28 weeks 
of gestation were considered only if the mean gestational age of 
participants was within the range of ≥ 14 to ≤ 28 weeks. 
The review included studies that compared regimens of mifepristone 
used in combination with misoprostol versus misoprostol alone, as well as 
those that compared different doses of misoprostol after administration 
of mifepristone, different doses of misoprostol with or without a loading 
dose, different routes of administration of misoprostol and different 
preparations of misoprostol (i.e. moistened or dry). 
Effects (benefits and harms) The reviewed studies showed that women treated with a combination 
of mifepristone and misoprostol had higher rates of complete 
abortion within 24 hours and a shorter expulsion time than those 
treated with misoprostol alone. For both combination regimens and 
misoprostol-only regimens, women treated with 400 μg misoprostol 
had higher rates of complete abortion within 24 hours and lower 
rates of serious adverse events than women treated with alternative 
dosages of misoprostol. In the studies that compared routes of 
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RECOMMENDATIONS
COMBINATION REGIMEN  
(RECOMMENDEDª)
MISOPROSTOL-ONLY  
(ALTERNATE)
MIFEPRISTONE   MISOPROSTOL MISOPROSTOL 
INTRAUTERINE FETAL DEMISE 
≥ 14–28 WEEKS
200 mg  
PO once
400 μg  
PV or SL  
 every 4–6 hoursb
400 μg  
SL (preferred) or PV 
 every 4–6 hoursb
a Combinat ion regimen is  recommended because i t  is  more effect ive.
b Repeat doses of  misoprostol  can be considered when needed to achieve success of  the abort ion process. In this  guidel ine we 
do not provide a maximum number of  doses of  misoprostol . Health-care providers should use caut ion and c l in ical  judgement 
to decide the maximum number of  doses of  misoprostol  in pregnant indiv iduals  with pr ior  uter ine incis ion. Uter ine rupture is  a 
rare compl icat ion; c l in ical  judgement and health system preparedness for  emergency management of  uter ine rupture must be 
considered with advanced gestat ional  age. 
1–2 DAYS
RECOMMENDATION 2
Medical management for intrauterine fetal 
demise at ≥ 14 to ≤ 28 weeks of gestation 8
PO: oral ; PV: vaginal ; SL: subl ingual
We suggest the use of 200 mg mifepristone administered orally, followed 1–2 days later by  
repeat doses of 400 μg misoprostol administered sublingually or vaginally every 4–6 hours.b  
The minimum recommended interval between use of mifepristone and misoprostol is 24 hours.
For the misoprostol-only regimen, we suggest the use of repeat doses of 400 μg misoprostol 
administered sublingually every 4–6 hours.b
Where sublingual misoprostol is not used, we suggest the use of repeat doses of 400 μg  
misoprostol administered vaginally every 4–6 hours.b
Notes: 
• Data related to gestational ages over 24 weeks of gestation were more l imited. 
• The use of a loading dose of misoprostol is not necessary. There is no advantage to the use of 
moistened over dry misoprostol. 
RECOMMENDATION TYPE: NEW OR UPDATED
Recommendation 2 is new.
8 In this guideline, duration of pregnancy (gestation) is the size of the uterus, estimated in weeks, based 
on clinical examination, that corresponds to a pregnant uterus of the same gestational age dated by last 
menstrual period (LMP).
  administration for misoprostol, there was no strong evidence of one 
route being superior to another.
 Values We were not able to identify research addressing the value placed 
on management of IUFD. Generally, we made the assumption that 
individuals would value shorter induction to expulsion times, and 
would value avoiding additional surgical intervention, serious adverse 
events and minor side-effects. However, there may be important 
variability in how much individuals value these outcomes, particularly 
in relation to each other. For example, a person may choose a longer 
induction to expulsion time if it is associated with a lower risk of 
serious adverse events and minor side-effects.
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Equity We were unable to identify research on aspects of equity related to the 
relative effectiveness of the intervention in different subgroups; no 
assumptions were made.
Resources We were unable to identify research that explored the costs involved or 
the cost-effectiveness of the intervention among the studies included 
in the systematic review. However, serious adverse events related to 
medical management of IUFD are rare. In cases where additional hospital 
resources are required, such as blood transfusion, inpatient management 
or analgesic measures, we assume that the costs associated with this care 
will be higher. We were unable to determine the impact that the use of 
mifepristone has on costs. While there may be an increased upfront cost 
in the delivery of a combination regimen (mifepristone and misoprostol), 
the overall resource use (and cost) may be decreased due to a shorter 
abortion process and higher success rates.
Acceptability Several factors impacting acceptability were considered in the 
development of this recommendation, including tolerability of 
medication. Overall, women were satisfied with their treatment 
(33–35) and found the pain associated with the induction less than or 
the same as they expected (35).
Feasibility We were unable to identify research on the feasibility of implementing 
the use of misoprostol alone or in combination with mifepristone for 
the management of IUFD at ≥ 14 to ≤ 28 weeks specifically. However, 
the 16 studies were conducted across 17 countries (one study was 
conducted across sites in two countries) providing information on the 
varying country contexts in which such services may be provided. Of 
these 17 countries, six were lower-middle-income economies, seven 
were upper-middle-income economies and four were high-income 
economies (32).
Rationale for Recommendation 2: Women treated with a 
combination of mifepristone and misoprostol had higher rates of 
successful abortion within 24 hours and a shorter expulsion time 
than those treated with misoprostol alone. The certainty of the 
evidence ranged from low to very low. Evidence suggests that in 
both combination regimens and misoprostol-only regimens, the use 
of 400 μg misoprostol leads to higher rates of successful abortion 
within 24 hours and lower rates of serious adverse events compared 
with other doses.
3.3.4  Additional considerations 
For the health-care providers managing IUFD at ≥ 14 to ≤ 28 weeks of 
gestation, the recommendations for cadres who can manage medical 
abortion at > 12 weeks can be followed. Alongside non-specialist 
and specialist doctors, additional cadres – including nurses, midwives 
and associate/advanced associate clinicians – can provide care 
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where there is access to appropriate surgical backup and the proper 
infrastructure is available to address incomplete abortion or other 
complications (10). Patient preference should be considered when 
determining the route of misoprostol administration in medical 
management.
3.3.5  Research gaps
General:
  Identification of the most effective medical regimen for IUFD 
management is needed. In particular, future research can 
investigate the efficacy of lower doses of misoprostol, such as 
200 μg, when used with mifepristone.
 Misoprostol dosage for management of IUFD at < 20 weeks 
versus 20–28 weeks of gestation should be investigated. 
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RECOMMENDATIONS
COMBINATION REGIMEN  
(RECOMMENDEDª)
MISOPROSTOL-ONLY  
(ALTERNATE)
MIFEPRISTONE   MISOPROSTOL MISOPROSTOL 
INDUCED ABORTION 
< 12 WEEKS
200 mg  
PO once
800 μg  
B, PV or SLb,c
800 μg  
  B, PV or SLb,c
a Combinat ion regimen is  recommended because i t  is  more effect ive. 
b Considerat ion for  pat ient and provider  preference suggests the inclusion of  a l l  routes, inc luding buccal  administrat ion.
c See note on next page ( for  Recommendation 3b). 
1–2 DAYS
RECOMMENDATION 3A
Medical management of induced 
abortion at < 12 weeks of gestation9
B: buccal ; PO: oral ; PV: vaginal ; SL: subl ingual
We recommend the use of 200 mg mifepristone administered orally, followed 1–2 days later by 
800 μg misoprostol administered vaginally, sublingually or buccally.b,c The minimum recommended 
interval between use of mifepristone and misoprostol is 24 hours.
For the misoprostol-only regimen, we recommend the use of 800 μg misoprostol administered 
vaginally, sublingually or buccally.b,c
Notes: 
•  There is l imited evidence to suggest that simultaneous dosing of mifepristone and misoprostol is 
efficacious (39,40). 
RECOMMENDATION TYPE: NEW OR UPDATED
Recommendation 3a has been updated from the WHO 2012 Safe abortion guidance (6). This updated 
recommendation applies to pregnancies up to 12 weeks of gestation, whereas in the prior guidance, 
different regimens were recommended for pregnancies up to 7 weeks, 9 weeks and 12 weeks. For 
the recommended misoprostol-only regimen, buccal route of administration has been added and the 
maximum number of doses has been removed. Interval dosing has been removed and a note has been 
added that repeat doses of misoprostol can be considered to achieve success of the abortion process.
9 In this guideline, duration of pregnancy (gestation) is the size of the uterus, estimated in weeks, based 
on clinical examination, that corresponds to a pregnant uterus of the same gestational age dated by last 
menstrual period (LMP).
3.4 Induced abortion
 3.4.1  Indication for induced abortion
People with an unplanned, mistimed or unwanted pregnancy may 
choose to have a medical abortion. Medical abortion refers to the 
sequential use of mifepristone followed by misoprostol or, in settings 
where mifepristone is not available, the use of misoprostol alone, 
to induce abortion, as an alternative to surgical management of 
abortion. An enabling regulatory and policy environment is needed 
to ensure that every individual who can become pregnant and who 
is legally eligible has ready access to safe abortion care. Laws and 
policies on abortion should protect health and human rights (6).
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RECOMMENDATIONS
COMBINATION REGIMEN  
(RECOMMENDEDª)
MISOPROSTOL-ONLY  
(ALTERNATE)
MIFEPRISTONE   MISOPROSTOL MISOPROSTOL 
INDUCED ABORTION   
≥  12 WEEKS
200 mg  
PO once
400 μg  
B, PV or SL  
  every 3 hoursb,c
400 μg  
B, PV or SL  
  every 3 hoursb,c
a Combinat ion regimen is  recommended because i t  is  more effect ive. 
b Evidence suggests that vaginal  route is  the most effect ive. Considerat ion for  pat ient and provider  preference suggests the 
inclusion of  a l l  routes, inc luding buccal  administrat ion.
c Repeat doses of  misoprostol  can be considered when needed to achieve success of  the abort ion process. In this  guidel ine we 
do not provide a maximum number of  doses of  misoprostol . Health-care providers should use caut ion and c l in ical  judgement 
to decide the maximum number of  doses of  misoprostol  in pregnant indiv iduals  with pr ior  uter ine incis ion. Uter ine rupture is  a 
rare compl icat ion; c l in ical  judgement and health system preparedness for  emergency management of  uter ine rupture must be 
considered with advanced gestat ional  age. 
1–2 DAYS
RECOMMENDATION 3B
Medical management of induced 
abortion at ≥ 12 weeks of gestation
B: buccal ; PO: oral ; PV: vaginal ; SL: subl ingual
We suggest the use of 200 mg mifepristone administered orally, followed 1–2 days later by repeat 
doses of 400 μg misoprostol administered vaginally, sublingually or buccally every 3 hours.b,c  
The minimum recommended interval between use of mifepristone and misoprostol is 24 hours.
For the misoprostol-only regimen, we suggest the use of repeat doses of 400 μg misoprostol 
administered vaginally, sublingually or buccally every 3 hours.b,c
Notes: 
•  The use of a loading dose of misoprostol is not necessary. There is no advantage to the use of 
moistened over dry misoprostol. 
RECOMMENDATION TYPE: NEW OR UPDATED
Recommendation 3b has been updated from the WHO 2012 Safe abortion guidance (6). For this 
recommendation, the combination regimen (mifepristone and misoprostol) does not have the loading 
dose of 800 μg misoprostol as in the prior guidance. For both the combination regimen and the 
misoprostol-only regimen, the buccal route has been added as an option. Maximum number of doses 
has been removed and the time period between mifepristone and misoprostol dosing is given in days. 
 3.4.2  Medical management of induced abortion: 
Recommendations 3a and 3b
The decision about abortion management should be based on the individual’s 
preference for treatment. The WHO guideline, Safe abortion: technical and 
policy guidance for health systems (2012), recommends manual or electric 
vacuum aspiration, dilation and evacuation, or medical management, either 
using a combination regimen (mifepristone followed by misoprostol) or 
misoprostol alone (6). Mifepristone followed by a prostaglandin analogue 
has been shown to be safe and effective (36). Limited evidence also suggests 
that a regimen with repeated doses of misoprostol between 9 and 12 weeks 
of gestation is safe and effective (4,28,37,38); however, use of misoprostol 
alone is less effective than its use in combination with mifepristone. 
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This guideline provides updated information related to specific 
dosages, routes and regimens for medical abortion, which differ for 
pregnancies of different gestational ages.
3.4.3  Evidence summary and rationale for 
Recommendations 3a and 3b
Three systematic reviews served as the evidence base for the 
effectiveness, safety and acceptability of medical management of 
induced abortion regimens using mifepristone plus misoprostol (the 
combination regimen) or misoprostol alone: the first was for induced 
abortions at ≤ 63 days of gestation (41); the second was for induced 
abortions at > 63 days and up to 84 days (42); and the third was for 
induced abortions at ≥ 12 weeks of gestation (43). 
In the first systematic review, 41 studies were included towards the 
development of this recommendation comparing the combination 
regimen to the use of misoprostol alone, and comparing 
different routes, doses and dosing intervals for misoprostol after 
administration of mifepristone, and different doses of misoprostol in 
misoprostol-only regimens (41). 
In the second systematic review, five studies were included towards the 
development of these recommendations comparing different routes 
of misoprostol administration after use of mifepristone, different 
doses of misoprostol administration in misoprostol-only regimens, and 
comparing the management of induced abortion in a health-care facility 
to self-management by the pregnant individual (42).
In the third systematic review, a total of 44 RCTs were identified for 
inclusion. The review included studies that compared the combination 
regimen with misoprostol alone. Studies also compared different 
doses of misoprostol after administration of mifepristone, different 
doses of misoprostol with or without a loading dose, different routes 
of administration of misoprostol, and different preparations of 
misoprostol (i.e. moistened or dry) (43).
Effects (benefits and harms) The first review, on induced abortions at ≤ 63 days of gestation (41), 
revealed that the combination regimen had higher rates of successful 
abortion and lower rates of ongoing pregnancy than the misoprostol-
only regimen. In the studies comparing misoprostol doses and interval 
of misoprostol administration in the combination regimen, there were 
higher rates of successful abortion and lower rates of ongoing pregnancy 
with 800 μg of misoprostol and an interval of at least 24 hours between 
use of mifepristone and misoprostol. Studies comparing the different 
routes of misoprostol administration revealed the vaginal and sublingual 
routes to be more effective. In the few studies that compared misoprostol 
dosages in misoprostol-only regimen, 800 μg of misoprostol had lower 
rates of ongoing pregnancy and higher rates of successful abortion.
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The second systematic review revealed that medical abortion is effective 
in the late first trimester (> 63 days and up to 84 days of gestation) (42). 
A combination regimen is significantly more effective than a 
misoprostol-only regimen. Success rates were higher with repeat dosing 
of misoprostol both in combination regimens and when misoprostol 
was used alone, and they were also higher with vaginal rather than 
oral administration for repeat dosing. Two studies addressed outpatient 
medical abortion, showing no significant difference in effectiveness, 
safety or acceptability between the two groups.
The third systematic review, on induced abortion at ≥ 12 weeks, 
showed that combination regimens had lower rates of ongoing 
pregnancy at 24 and 48 hours when compared with misoprostol-only 
regimens. Dosing of mifepristone 24 hours before misoprostol had 
lower rates of ongoing pregnancy when compared to simultaneous 
dosing of both medications. In misoprostol-only regimens, dosing 
intervals of 3 hours had lower rates of ongoing pregnancy at 24 and 
48 hours compared to other dosing intervals. For both combination 
and misoprostol-only regimens, sublingual and vaginal misoprostol 
routes of administration had better efficacy and lower rates of 
side-effects than the oral route (43). 
Values We were unable to identify research on values relating to the 
management of medical abortion. We made the assumption that 
individuals value outcomes of effectiveness and safety, but it is 
unclear how they would value those outcomes when weighed against 
side-effects and markers of acceptability.
Women may also strongly value certain interventions over others, 
with preferences for route and timing of medication administration, 
and type of intervention (medical or surgical) differing significantly 
between one woman and another, or one region of the world and 
another (44–46). Consideration should also be given to the value 
women place on the timing and cost of abortion services as well as 
opportunities to take part in managing their own abortion care in 
situations where at-home dosing or abortion self-management are 
available (47–49).
Equity We were unable to identify research on aspects of equity around 
relative effectiveness of the interventions in different subgroups. 
However, in 4 studies, participants ranged in age from 16 to 44 years, 
demonstrating inclusion of people across age groups (50–53).
Resources In the studies included in the three systematic reviews, we were 
unable to identify research that explored the costs involved or the 
cost-effectiveness. Studies on medical abortion include analgesic 
options ranging from oral to parenteral administration, including 
opiates, depending on gestational age. In cases where additional 
An enabling regulatory 
and policy environment 
is needed to ensure that 
every individual who can 
become pregnant and 
who is legally eligible 
has ready access to 
safe abortion care.
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hospital resources are required, such as blood transfusion, inpatient 
management, analgesic measures or foeticide, we assume that the 
costs associated with these services will be higher. We were unable to 
determine the impact that the use of mifepristone has on costs. While 
there may be an increased upfront cost with the use of a combination 
regimen, the overall resources used may be decreased due to a shorter 
abortion process and a higher success rate.
Feasibility We were unable to identify research on the feasibility of implementing 
the use of misoprostol alone or in combination with mifepristone 
for the management of medical abortion. However, four studies 
conducted in women with pregnancies 9–12 weeks of gestation 
reported that the medical abortion service was provided as outpatient 
care indicating feasibility of offering the service through outpatient 
health-care facilities (33,50,51,53). Additionally, studies related to 
management of medical abortion at < 12 weeks of gestation were 
conducted across 10 countries: two high-income, three upper-middle-
income, four lower-middle-income and one low-income economy (41). 
Studies related to management of medical abortion at ≥ 12 weeks 
of gestation were conducted across 23 countries (four studies were 
conducted across sites in multiple countries): one was a low-income 
economy, six were lower-middle-income economies, five were upper-
middle-income economies, and 11 were high-income economies (43).
Acceptability Generally, women find various routes of misoprostol administration 
acceptable (48,49,54–59). Additionally, women found the side-effects 
to be acceptable (47,49). Women receiving care for management of 
medical abortion at < 12 weeks of gestation reported that the ability 
to predict timing of the bleeding was the best feature of taking the 
medicines at home (51). Home use of medical abortion at < 12 weeks 
gestation following an interaction with a health-care provider enabled 
women to keep working or reduced opportunity costs (51).
Rationale for Recommendation 3a (on medical abortion at 
< 12 weeks of gestation): The combination mifepristone and 
misoprostol regimen is based on moderate certainty of evidence 
for induced abortion at < 12 weeks. In combination regimens, 
misoprostol dosage of 800 μg administered vaginally, sublingually or 
buccally is recommended based on moderate certainty of evidence. 
Evidence is limited regarding the use of misoprostol-only regimens, 
especially between 9 and 12 weeks of gestation. Thus, the GDG 
members took the view that when using misoprostol-only regimens, 
the dose of 800 μg administered vaginally, sublingually or buccally is 
safe, effective and acceptable.
Rationale for Recommendation 3b (on medical abortion at ≥ 12 
weeks of gestation): The combination mifepristone and misoprostol 
regimen is based on moderate certainty of evidence for induced 
Women receiving care for 
management of medical 
abortion at < 12 weeks of 
gestation reported that the 
ability to predict timing 
of the bleeding was the 
best feature of taking the 
medicines at home (51).
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abortion at ≥ 12 weeks. Mifepristone 200 mg is suggested based on 
success, women’s values and cost (given the higher price of 600 mg 
of mifepristone) based on low to very low certainty of evidence. 
Misoprostol dosage of 400 μg administered every 3 hours is suggested 
based on overall very low certainty of evidence and is conditional 
upon resources available in different settings. Evidence on use of 
the buccal route was inconclusive, but it should be considered as an 
acceptable option if an individual prefers this route of administration. 
This is based on low to very low certainty of evidence. 
3.4.4  Additional considerations
Given the nature of the medical abortion process when using the 
combination regimen, it is possible for individuals to play a role in 
managing some of the components by themselves outside of a health-care 
facility. Where there is access to a source of accurate information and to 
a health-care provider (should one be needed or wanted at any stage of 
the process), the abortion process can be self-managed with pregnancies 
<12 weeks of gestation without the direct supervision of a health-care 
provider (10) (evidence is limited for pregnancies > 10 weeks [53,60–64]). 
For provision of medical abortion of pregnancies < 12 weeks, the 
following cadres have been recommended: auxiliary nurses, auxiliary 
nurse midwives, nurses, midwives, associate/advanced associate clinicians, 
and non-specialist and specialist doctors. Doctors of complementary 
systems of medicine can be providers of this service in health system 
contexts with an established mechanism for the participation of such 
doctors in other tasks related to maternal and reproductive health (10).
Alongside non-specialist and specialist doctors, the following cadres can 
provide medical abortion for pregnancies ≥ 12 weeks in contexts where 
appropriate surgical backup and proper infrastructure is established and 
easily accessible to address incomplete abortion or other complications: 
nurses, midwives, associate/advanced associate clinicians (10).
3.4.5  Research gaps
General:
 The various next steps that individuals can take, if needed, after 
medical abortion should be further evaluated. This includes 
self-assessment of the success of medical abortion, in particular 
for misoprostol-only regimens, which tend to be used in more 
restrictive settings and which are less effective.
  For those with uterine scars, the safety and efficacy of medical 
abortion regimens is an area requiring more research. In particular, 
the misoprostol dosage when used in combination with mifepristone 
and when used in misoprostol-only regimens for pregnancies 13–20 
weeks versus 20–28 weeks of gestation can be investigated.
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  Additional evidence is needed on the cost-effectiveness of all 
medical abortion interventions. 
 Qualitative research is needed on individuals’ values and 
preferences relating to all medical abortion interventions. 
Medical abortion at < 12 weeks of gestation:
  Studies are needed on the efficacy, safety and acceptability of 
medical abortion (combination mifepristone and misoprostol 
regimens and misoprostol-only regimens) in the outpatient setting 
for pregnancies 9–12 weeks of gestation. This includes the follow-
up care for medical abortion when self-assessment is used to 
determine eligibility for and success of the medical abortion. 
Medical abortion at ≥ 12 weeks of gestation:
 Studies are needed to determine the gestational age limit within 
which it is safe to carry out medical abortion without hospital 
admission. 
  In connection to the research gap noted above, qualitative research will 
also be needed on the acceptability of outpatient medical abortion.
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 3.5 Post-abortion 
contraception
 3.5.1  Provision of post-abortion contraception
Contraception can be initiated at the time of administration of the 
first pill of the medical abortion regimen or after assessment of 
successful medical abortion. All contraceptive options may be used. 
Criteria laid out in the WHO publications Medical eligibility criteria 
for contraceptive use and Ensuring human rights in the provision of 
contraceptive information and services should be adhered to (65,66).
CONTRACEPTIVE METHOD
POST-ABORTION CONDITION
FIRST 
TRIMESTER
SECOND 
TRIMESTER
IMMEDIATE  
POST-SEPTIC 
ABORTION
COMBINED ORAL CONTRACEPTIVES (COCS ) 1 1 1
COMBINED INJECTABLE CONTRACEPTIVES (CICS ) 1 1 1
PATCH & VAGINAL RING 1 1 1
PROGESTERONE-ONLY PILLS (POPS ) 1 1 1
PROGESTOGEN-ONLY INJECTABLES: DMPA, NET-EN 
(depot medroxyprogesterone acetate, norethisterone enanthate)
1 1 1
PROGESTOGEN-ONLY IMPLANTS: LNG, ETG 
( levonorgestrel, etonogestrel)
1 1 1
COPPER-BEARING INTRAUTERINE DEVICE ( IUD) 1 2 4
LNG-RELEASING IUD 1 2 4
CONDOMS 1 1 1
SPERMICIDE 1 1 1
DIAPHRAGM 1 1 1
DEFINITION OF CATEGORIES
1.  A condition for which there is no restriction for the use of the contraceptive method.
2.  A condition where the advantages of using the method generally outweigh the theoretical or proven risks.
3.  A condition where the theoretical or proven risks usually outweigh the advantages of using the method.
4.  A condition that represents an unacceptable health risk if the contraceptive method is used.
Source: WHO (2015) (65)
TABLE 3
Post-abortion medical eligibility recommendations 
for contraceptive methods
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TIMING OF POST-ABORTION CONTRACEPTION
IMMEDIATE INITIATION
HORMONAL CONTRACEPTION Immediately after the first pill of the medical abortion
RECOMMENDATION 4A
Timing of post-abortion hormonal contraception 
initiation, except for intrauterine device (IUD)
For individuals undergoing medical abortion with the combination mifepristone and misoprostol 
regimen or the misoprostol-only regimen who desire hormonal contraception (oral contraceptive  
pills, contraceptive patch, contraceptive ring, contraceptive implant or contraceptive injections),  
we suggest that they be given the option of starting hormonal contraception immediately after  
the first pill of the medical abortion regimen.
Notes: 
•  All individuals who can become pregnant should be provided with all of the necessary information to 
make an informed decision regarding the use of contraception. Immediate initiation of intramuscular (IM) 
depot medroxyprogesterone acetate (DMPA) is associated with a slight decrease in the effectiveness of 
medical abortion regimens (67). However, immediate initiation of DMPA should still be offered as an 
available contraceptive method after an abortion.
•  Indirect evidence was used as a basis for decision-making on initiation of hormonal contraception as an 
option for individuals undergoing medical abortion with misoprostol alone.
•  No data were available on the use of combined hormonal contraception (pills or injections) by those 
undergoing medical abortion.
RECOMMENDATION TYPE: NEW OR UPDATED
Recommendation 4a is a new recommendation.
3.5.2  Timing of post-abortion contraception: 
Recommendations 4a and 4b
The following recommendations provide further clarification on the 
timing of initiating contraception after a medical abortion. 
3.5.3  Evidence summary and rationale for 
Recommendations 4a and 4b
Three systematic reviews served as the evidence base for the 
timing of post-abortion contraception. The first systematic review 
assessed the efficacy and safety of non-IUD hormonal contraception 
initiation after abortion (including medical abortion) (68). Three 
RCTs (67,69,70) and one cohort study (71) compared immediate 
versus delayed initiation of implants or DMPA after medical 
abortion with mifepristone and misoprostol. No studies assessed 
hormonal contraception initiation after medical abortion with a 
misoprostol-only regimen. 
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TIMING OF POST-ABORTION CONTRACEPTION
IMMEDIATE INITIATION
IUD With assessment of successful abortion
RECOMMENDATION 4B
Timing of post-abortion intrauterine 
device (IUD) placement
For individuals undergoing medical abortion with the combination mifepristone and misoprostol regimen 
or the misoprostol-only regimen who wish to have an IUD inserted, we suggest IUD placement at the time 
that success of the abortion procedure is determined. The use of clinical signs with bimanual examination, 
serum human chorionic gonadotrophin (hCG) levels or ultrasonography (if available), and an assessment of 
the individual’s current symptoms can be used to determine whether or not there is an ongoing pregnancy.
RECOMMENDATION TYPE: NEW OR UPDATED
Recommendation 4b is a new recommendation. 
 
The second systematic review assessed contraceptive continuation at six 
months (implants, DMPA and IUD) and unintended pregnancies after the 
index abortion (72). This review included the same three RCTs (67,69,70) 
and one cohort study (71) that were included in the first review. 
The third systematic review assessed the effectiveness and safety of 
initiation of IUD after abortion (73). In this review, three studies compared 
immediate versus delayed IUD insertion after medical abortion with 
mifepristone and misoprostol (74–76). The included studies assessed 
copper-bearing and levonorgestrel-releasing IUDs. No studies assessed 
IUD initiation after medical abortion with a misoprostol-only regimen. 
 Effects (benefits and harms) The findings of the three RCTs and one cohort study in the first 
systematic review (68) showed that there was little difference in the 
rates of successful abortion between the two groups (immediate 
versus delayed initiation of implants or DMPA after medical abortion) 
and satisfaction regarding the timing of their contraception initiation 
was high. Findings from the same studies, which were also reviewed 
in the second systematic review (72), showed that continuation rates 
at six months were higher for the women in the immediate initiation 
group. Contraceptive failure rates were lower among women who 
initiated the implant, DMPA or the IUD immediately. The studies on 
immediate versus delayed IUD insertion after medical abortion in the 
third systematic review (73) showed that there was no difference 
between the immediate and delayed insertion groups with regard 
to adverse events or the need for further intervention after IUD 
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placement. There were fewer expulsions of the IUD at 12 months 
among women who had undergone immediate IUD placement.
 Values Women placed high value on accepting a contraceptive method to 
prevent a future pregnancy. Two studies looking at DMPA and 
implants reported that women undergoing an abortion placed high 
importance on preventing a pregnancy in the next six months (67,70).
 Resources In regard to resource requirements and cost-effectiveness, there was 
no direct research evidence that explored these domains. The cost 
of the IUD and implant versus pills and injections in various country 
contexts could not be determined. While there may be increased 
upfront costs of the IUD and implant, related to the cost of the 
devices, provider training and additional placement and removal 
visits, costs may decrease over time compared with the repeated 
need for pills and injections (77).
 Equity There was no research evidence identified on aspects of equity around 
the relative effectiveness of the intervention in different subgroups. 
However, three studies included adolescents (67,70,71) and three 
studies included nulliparous women (74–76).
 Acceptability Women reported high satisfaction with immediate initiation of their 
implant or DMPA administration (67,70). Acceptability and satisfaction 
were also reported by women in the immediate-start group based 
on fewer visits made to the health-care provider compared with the 
delayed-start group (70). Immediate initiators of implants had higher 
attendance at follow-up appointments (69,71).
For the IUD studies, similar considerations were taken into account. 
None of the included studies specifically addressed acceptability of 
the service to women. However, timing of insertion can be used as a 
proxy indicator for acceptability; more women had the IUD placed at 
the time that successful abortion was determined compared with the 
number of women who opted for delayed insertion (74,76). The rate 
of loss to follow-up at six months was reportedly lower for the ear-
ly-insertion group as compared with the delayed insertion group (75).
 Feasibility Initiation of post-abortion contraception appears feasible to implement. 
The included studies for both IUD and hormonal contraception were 
conducted through outpatient clinics, indicating feasibility of offering 
the service through outpatient health-care facilities.
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Rationale for Recommendation 4a (on post-abortion hormonal 
contraception initiation, except for IUD): There was little 
difference in the successful abortion rates between women who 
started non-IUD hormonal contraception after receiving mifepristone 
versus those who started after receiving both mifepristone and 
misoprostol. This difference was based on low certainty of evidence. 
Women placed value on accepting a contraceptive method and they 
placed value on preventing future pregnancies. Satisfaction with and 
acceptability of immediate initiation of a contraceptive method was 
high. Continuation rates for the implant at six months were higher 
for the women in the immediate-initiation group. The certainty of the 
evidence was very low.
Rationale for Recommendation 4b (on post-abortion IUD 
placement): Placement of an IUD at the time the abortion process has 
been deemed successful leads to lower rates of contraceptive failure 
and higher continuation rates at 6 and 12 months. The 6-month 
continuation rates are based on moderate certainty of evidence while 
the contraceptive failure rates are based on low certainty of evidence 
and the continuation rates at 12 months are based on very low 
certainty of evidence. There is no difference in the number of women 
requiring further intervention post-IUD placement due to retained 
tissue or bleeding, but the certainty of the evidence was low. There 
is no difference in the side-effect of pain at IUD insertion between 
the two groups, based on moderate certainty of evidence. Serious 
adverse events are rare and there was no difference between the two 
groups for uterine perforation or death, but this was based on very 
low certainty of evidence. Acceptability and feasibility of immediate 
placement of the IUD was high. 
 3.5.4  Additional considerations
All individuals who can become pregnant should be informed that 
ovulation can return within two weeks following abortion, putting 
them at risk of pregnancy unless an effective contraceptive method is 
used. Those who are interested in contraception should be provided 
with accurate information to assist them with choosing the most 
appropriate contraceptive method to meet their needs. Some prefer 
to discuss options for contraception after the abortion is completed. 
For those seeking an abortion following a reported contraceptive 
failure, it is important to discuss whether the method may have been 
used incorrectly and how to use it correctly, or whether it may be 
appropriate to change to a different method. Ultimately, the final 
decision about whether to use contraception, and which method to 
use, is up to the individual alone (19).
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IMPORTANT NOTE: Acceptance of a contraceptive method must 
never be a precondition for providing an abortion. 
For the health workforce, task sharing guidelines have offered options 
for various cadres to conduct different aspects of the provision of 
contraception counselling and services (10,78).
For injectable contraception administration, the following cadres 
have been recommended: auxiliary nurses, auxiliary nurse midwives, 
nurses, midwives, pharmacists, associate/advanced associate clinicians, 
and non-specialist and specialist doctors. Doctors of complementary 
systems of medicine can be providers of this service in health system 
contexts with an established mechanism for the participation of such 
doctors in other tasks related to maternal and reproductive health. 
Pharmacy workers can administer the injectable contraceptive under 
direct supervision of a pharmacist. Lay health works as administrators 
of injectable contraception can be an option if conducted under 
targeted monitoring and evaluation (10).
For implant insertion and removal, the following cadres have been 
recommended: nurses, midwives, pharmacists, associate/advanced 
associate clinicians, and non-specialist and specialist doctors. Auxiliary 
nurses and auxiliary nurse midwives may perform implant insertion/
removal within the context of targeted monitoring and evaluation. 
Doctors of complementary systems of medicine can be providers of 
this service in health system contexts with an established mechanism 
for the participation of such doctors in other tasks related to maternal 
and reproductive health and where training in implant removal is 
given along with training in insertion (10).
For IUD placement, the following cadres have been recommended: 
auxiliary nurse midwives, nurses, midwives, associate and advanced 
associate clinicians, non-specialist and specialist doctors. Doctors of 
complementary systems of medicine can be providers of this service 
in health system contexts with an established mechanism for the 
participation of such doctors in other tasks related to maternal and 
reproductive health (10).
Self-administration of injectable contraception is an option in contexts 
where mechanisms to provide appropriate information and training 
exist, referral linkages to health-care providers are strong, and 
monitoring and follow-up can be ensured (10). 
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 3.5.5  Research gaps
General:
 Studies are needed on the efficacy, safety and acceptability of 
immediate initiation of contraception with misoprostol-only 
regimens. 
 Studies on the efficacy, safety and acceptability of the initiation 
of combined hormonal contraception at the time of mifepristone 
administration are also lacking.
 Recommendations on the timing of post-abortion contraception 
are inclusive of combined hormonal contraception and 
misoprostol-only regimens, based on indirect evidence. Results 
from the survey on research gaps (completed by GDG members) 
noted the lack of direct evidence for these clinical scenarios and, 
therefore, further research on this topic should be pursued.
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General implementation considerations for the recommendations in this 
guideline are outlined below through a question-and-answer format. 
IMPORTANT NOTE: The quality of medicines used is an important 
factor that can influence the process and overall success of a 
medical abortion. Substandard mifepristone and/or misoprostol 
products that do not contain the right active ingredients in the 
right dosages, and those that are not manufactured, transported or 
stored under the specified conditions, can affect the outcomes of 
a medical abortion. It is critical that mifepristone and misoprostol 
used for medical abortion are properly manufactured in line with 
specifications and are handled appropriately through the supply 
chain until use at the point of care. Ensuring use of quality-assured 
mifepristone and misoprostol that has been transported and stored 
correctly according to the specified conditions can contribute to the 
overall quality of a medical abortion process.
Q:  Where should medical abortion services be available?
A:  Services should be available at the primary-care level, with referral 
systems in place for all required higher-level care. 
Q:  Who can provide these medical abortion services?
A:  In addition to non-specialist doctors and specialist doctors, with 
task-specific training and functioning systems for monitoring and 
supportive supervision, a wide range of health worker cadres 
– such as auxiliary nurses, auxiliary nurse midwives, nurses, 
midwives, associate/advanced associate clinicians, pharmacists and 
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of medical abortion services. In addition, indirect evidence from a 
qualitative systematic review on factors affecting implementation 
of task sharing in abortion identified that some providers in 
a middle-income setting where abortion is legal saw medical 
abortion as having a number of benefits for health services (9). 
These reported benefits included that it was safe and effective; 
it would reduce the burden on health services; and it may make 
it easier for people involved to act in accordance with their 
conscience. A discussion of general considerations for task shifting 
in maternal health and family planning can be found in the 2012 
OptimizeMNH guideline: WHO recommendations: optimizing 
health worker roles to improve access to key maternal and 
newborn health interventions through task shifting (78).
The specific cadres able to provide medical abortion services have 
been outlined in the additional considerations section for each 
recommendation. 
Q:  Can medical abortion processes be self-managed? 
A:  When using the combination mifepristone and misoprostol 
regimen, the medical abortion process can be self-managed for 
pregnancies up to 12 weeks of gestation, including the ability 
to take the medications at home, without direct supervision of a 
health-care provider (10); it should be noted that there was limited 
evidence for pregnancies beyond 10 weeks (53,60–64). This is 
an option in circumstances where individuals have a source of 
accurate information and access to a health-care provider should 
they need or want it at any stage during the process (10). 
Q:  What general considerations should be taken into account 
when providing care to adolescents/youth?
A:  Ensure that you are fully aware of the national and local laws and 
policies. In your work with adolescents, you may find that in some 
situations, prevailing laws and policies may not permit you to do what 
is in the best interests of your adolescent patient (e.g. in some places, 
the provision of contraceptives to unmarried adolescents is illegal). In 
such situations, you may need to draw upon your experience and the 
support of caring and knowledgeable people to find the best way to 
balance your legal obligations with your ethical obligations (13).
Provide information on the implications of each treatment option 
and help the adolescent choose the one best suited to his/her 
needs. While doing this: 
 present all the relevant information; 
 respond to questions as fully and honestly as you can; 
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 help them choose; and
 respect their choice, even if it is not the one you would have 
wanted them to make.
 Adolescents may be reluctant to disclose information on sensitive 
matters if their parents, guardians or spouses are also present.
 Reduce the stigma around the issue by normalising it: an 
adolescent who has an unwanted pregnancy or a sexually 
transmitted infection may feel embarrassed or even ashamed. 
You can reduce the stigma around the issue by saying to the 
adolescent, “I have treated a number of young people with the 
same problem you have.”
Q:  What considerations should be taken into account when 
conducting a clinical interview and examination with 
adolescents/youth?
A:  Following is list of considerations and steps.
 Respect local sensitivities regarding gender norms (e.g. 
whether it is appropriate for a male health worker to examine 
a female patient). If needed, ensure the presence of a female 
colleague during the examination (13).
 Ensure privacy (e.g. make sure that curtains are drawn, doors 
are shut and that no unauthorized person enters the room 
during the examination).
 Start the clinical interview with issues that are the least 
sensitive and least threatening; it is often best to ask first 
about the activities of their peers and friends rather than 
directly about their own activities.
 If the adolescent is with an accompanying person, reach an 
agreement as to whether they want this person to be present 
during the examination. 
 Inform the adolescent about what examination you want to 
carry out and the purpose of the examination.
 Explain the nature of the examination.
 Obtain the consent of the adolescent.
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A:  Physical examination to assess uterine size (i.e. bimanual pelvic 
and abdominal examination), assessment of last menstrual period 
(LMP) and recognition of symptoms of pregnancy are usually 
adequate. Laboratory or ultrasound testing may also be used, 
if needed. Laboratory testing is needed when typical signs of 
pregnancy are not clearly present and the provider is unsure 
whether there is an ongoing pregnancy. Obtaining tests should 
not hinder or delay uterine evacuation. Ultrasound scanning is 
not routinely required. Where it is available, it can help identify an 
intrauterine pregnancy and exclude an ectopic pregnancy (6,19).
Q:  How can success of the medical abortion be determined?
A:  Success of medical abortion is determined by signs and symptoms 
as experienced by the individual. These may include heavy 
bleeding with clots, passage of the products of conception, and 
pain that may be significantly stronger than normal menstrual 
cramps. If ongoing symptoms of pregnancy are reported and/or there 
has only been minimal or no bleeding after taking the medications 
as directed, ongoing pregnancy should be suspected and further 
evaluation could include pelvic examination (demonstrating a 
growing uterus) or an ultrasound scan (demonstrating an ongoing 
pregnancy) (19).
Q:  What is the role of ultrasound in these recommendations?
A:  Ultrasound scanning is not routinely required for the provision 
of abortion (6). Successful abortion may be confirmed by pelvic 
examination, pelvic ultrasound or a repeat hCG measurement. If 
serum hCG measurements are used, it should be remembered that 
in some cases low hCG levels can be detectable for up to four 
weeks after successful expulsion. Ultrasound is useful to detect 
ongoing pregnancy by measuring endometrial thickness; it should 
be noted, however, that endometrial thickness is not useful for 
diagnosing incomplete abortion and its use as an indicator for this 
purpose may lead to inappropriate surgical interventions (6).
For initiation of contraception, an ultrasound is not needed. Non-
IUD methods can be started immediately. IUDs can be inserted 
whenever the medical abortion has been deemed successful (19).
Q:  Is there a maximum number of doses of misoprostol that can 
be used in the medical management of abortion?
A:  Repeat doses of misoprostol can be considered when needed to 
achieve success of the abortion process. In this guideline we do 
not provide a maximum number of doses of misoprostol. Health-
care providers should use caution and clinical judgement to 
decide the maximum number of doses of misoprostol in pregnant 
individuals with prior uterine incision. Uterine rupture is a rare 
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complication; clinical judgement and health system preparedness 
for emergency management of uterine rupture must be considered 
with advanced gestational age. 
Q:  What is the best way to store misoprostol?
A:  Aluminium blister packs are the best way to store misoprostol (79). 
Cutting the blister pack and storing misoprostol outside the  
aluminium blister may increase the risk of damage to the packaging  
(i.e. the inner seal), leading to exposure to environmental 
conditions (80).
Store misoprostol in dry conditions at temperatures at or below 
25 °C (77 °F) (79,81).
Exposure to heat and humidity during manufacturing, packaging 
and storage may compromise the quality of misoprostol (81).
Q:  What is the best way to store mifepristone?
A:  Store at 25 °C (77 °F); excursions permitted between 15 °  
and 30 °C (59 ° and 86 °F) (82).
Q:  When does return to ovulation occur after a medical abortion?
A:  Ovulation can occur as few as eight days after a medical 
abortion (83).
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10 The webpage for this guideline, all language versions and related products is: http://www.who.int/reproductivehealth/publications/medical-management-abortion/en/  
11 Available at: www.who.int/rhl
Dissemination and adaptation
Translation of this guideline into Spanish (in collaboration with PAHO), French and Portuguese is planned. 
Versions in other United Nations languages will be developed as needed. Third-party translations into 
additional non-United Nations languages will be encouraged, provided they comply with WHO guidance 
on such translations. 
The digital versions of the guideline in all languages will be available via the WHO website10 and through the 
WHO Reproductive Health Library (RHL) website.11 Print versions of this guideline will be distributed to WHO 
regional and country offices, nongovernmental organization (NGO) partners, professional associations and other 
networks and partners. 
WHO regional offices are expected to be active partners in the dissemination and adaptation of these 
guidelines. A number of other interested agencies and NGOs are encouraged to partner with WHO in the 
dissemination and local adaptation of the guidelines and in developing derivative informational materials.
The guideline will be launched in WHO regions through regional dissemination meetings and specific 
knowledge transfer and adaptation activities and implementation research will take place in select countries 
based on need and interest to move ahead with implementation of the recommendations. Derivative products 
will be developed, such as simple pocket-sized charts. 
Guideline impact evaluation and future updates
Two years after publication of the guideline, an online survey will be conducted through WHO regional and 
country offices and selected respondents representing other user groups (e.g. professional societies, NGOs). 
The purpose of the survey will be to gauge in-country progress in utilization of the guideline, implementation of 
the recommendations and any influence on policy decisions. It will also help in gathering feedback relevant to 
future modifications of the guidance. 
Evidence will be reviewed and the guideline updated in four years, or earlier if new evidence warrants an update. 
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